Considering the relationship between therapy resistance and SPHK1 in other cancers, we hypothesise that the elevated SPHK1 in relapse ovarian cancer may be contributing to therapy resistance in HGSOC. This evidence concerns the gene SPHK1 and ovarian cancer.